Half the Patients Saw Dramatic Spleen Shrinkage: SENTRY Trial Shows Strong Results (With One Notable Miss) for New Myelofibrosis Combo

Karyopharm’s (KPTI) SENTRY trial delivers strong spleen reduction and promising survival data with selinexor + ruxolitinib — though symptom improvement was not superior. $30M cash boost extends runway into late 2026.